A holistic approach that takes into account all aspects of patient care – from treatment to nutrition, physical activity, and rehabilitation – could be a powerful tool to improve survival and quality of life in breast cancer.
A woman developed sudden painless ecchymosis (bruising) of her breast, which was thought to be related to the radiotherapy she received for early-stage breast cancer a year and a half earlier.
Nasopharyngeal carcinoma is known for its high potential to metastasize, but breast metastasis is rare. The authors describe the first case of synchronous breast metastases in a male patient.
Great progress has been made in developing strategies to manage malignant pleural effusion, but these still primarily focus on optimal drainage. More research is needed to advance understanding of mechanistic drivers and develop targeted therapies.
Olanzapine 2.5 mg is noninferior to the standard 10.0 mg dose for controlling chemotherapy-induced nausea and vomiting in people with cancer, and results in less daytime somnolence.
The treatment landscape of hormone receptor-positive, HER2-negative metastatic breast cancer has evolved dramatically in recent years. To assist in decision making, the authors review the existing data on systemic therapies and propose a treatment algorithm.
The results of a global study suggest no apparent detrimental effect of pregnancy after breast cancer on maternal prognosis or fetal outcomes in BRCA mutation carriers.
Mucoepidermoid carcinoma of the breast is a rare type of salivary gland-like tumor that generally displays a triple-negative phenotype. This case is the first to demonstrate HER2 gene amplification.
A Finnish study has found that the inverse association between statin use and breast cancer mortality may be mediated by the underlying cholesterol levels.
Neuromuscular, musculoskeletal, and lymphovascular complications are common after mastectomy. Cancer rehabilitation and other strategic interventions play a pivotal role in managing these challenges.
The prognosis of people with breast cancer and brain metastases or leptomeningeal disease is poor, but with more systemic treatment options becoming available, outcomes are improving.
Development of new anti-HER2 drugs and widespread adoption of the policy of continuing HER2 blockade beyond progression has improved the outcomes of people with advanced HER2-positive breast cancer.
Interventional procedures, such as botulinum toxin injections and nerve blocks, can help manage post-mastectomy pain syndrome in breast cancer patients when used alongside physical therapy and pharmacologic interventions.
The key clinical trial results for agents targeting the PI3K/AKT/mTOR signaling pathway in cancer are outlined and the major mechanisms of resistance to these inhibitors are discussed.
Preliminary MASAI trial results indicate that AI-supported mammography has a similar rate of breast cancer detection to standard double reading while reducing the screen-reading workload.
Liquid biopsy has shown considerable promise for cancer diagnosis, prognosis, and monitoring of response and recurrence. This review discusses the strengths and current limitations of the approach in the management of cancer.
